Core Viewpoint - Zhejiang Anglikang Pharmaceutical Co., Ltd. has received the approval notice for the listing application of the chemical raw material drug Bupivacaine from the National Medical Products Administration, which will enhance the company's product line and core competitiveness [1][4]. Group 1: Approval Information - The chemical raw material drug approved is Bupivacaine, with registration number Y20230001273 [1]. - The application for the drug was submitted in December 2023, accepted in January 2024, and recently approved [2]. Group 2: Product Application - Bupivacaine is primarily used in clinical settings for local anesthesia and postoperative analgesia [3]. Group 3: Impact on the Company - The approval of Bupivacaine will enrich the company's product line and enhance its core competitiveness [4].

Core Viewpoint - Recently, the company announced that it has received approval from the National Medical Products Administration for the marketing application of the chemical raw material drug Bupivacaine [2] Group 1 - The company is Zhejiang Anglikang Pharmaceutical Co., Ltd. [2] - The approved chemical raw material drug is Bupivacaine [2] - The announcement was made on the evening of November 17 [2]

Core Viewpoint - The stock of Shuoshi Biotechnology fell nearly 15% in the afternoon, with several other companies including Anglikang, Wanbangde, Kanglong Huacheng, Meidixi, Haoyuan Pharmaceutical, Jindike, and Jinshiyao also experiencing declines of over 5% [1] Company Performance - Shuoshi Biotechnology's stock decline of nearly 15% indicates significant market volatility [1] - Other companies in the sector, such as Anglikang and Wanbangde, also faced notable stock price drops, suggesting a broader trend affecting multiple firms [1] - The overall performance of the biotechnology sector appears to be under pressure, as indicated by the collective decline of several key players [1]

Core Viewpoint - Anglikon has received approval from the National Medical Products Administration for its chemical raw material drug, Bupivacaine, which meets the registration requirements for pharmaceuticals [1] Group 1: Company Information - Anglikon announced the receipt of the approval notice for the marketing application of Bupivacaine [1] - Bupivacaine is primarily used in clinical settings for local anesthesia and postoperative analgesia [1]

Core Viewpoint - The company, Anglikang (002940.SZ), has received approval from the National Medical Products Administration for the marketing application of the chemical raw material drug, Bupivacaine, which is primarily used for local anesthesia and postoperative analgesia [1] Group 1 - The drug Bupivacaine is a chemical raw material approved for marketing [1] - The approval is significant for clinical applications in local anesthesia and postoperative pain management [1]

Core Viewpoint - The company, Anglikang (002940.SZ), has received the approval notification from the National Medical Products Administration for the marketing application of the chemical raw material drug, Bupivacaine, which is primarily used for local anesthesia and postoperative analgesia [1] Group 1 - The drug Bupivacaine is a chemical raw material approved for marketing [1] - The approval is significant for the company's product portfolio in the anesthetic market [1] - Bupivacaine is clinically used for local anesthesia and postoperative pain relief [1]

Core Viewpoint - The company Anglikon (002940.SZ) has received approval from the National Medical Products Administration (NMPA) for the marketing application of its chemical raw material drug, Bupivacaine, which is primarily used for local anesthesia and postoperative analgesia [1] Group 1 - The approval notification was issued by the NMPA, indicating regulatory compliance and readiness for market entry [1] - Bupivacaine is a significant product in the field of anesthesia, enhancing the company's portfolio in the pharmaceutical industry [1]

证券代码：002940 证券简称：昂利康 公告编号：2025-088 浙江昂利康制药股份有限公司 关于获得化学原料药上市申请批准通知书的公告 申请内容：境内生产化学原料药上市申请 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，本品 符合药品注册的有关要求，批准注册。 二、产品基本情况 公司于 2023 年 12 月递交了布比卡因原料药的药品注册申请，于 2024 年 1 月获得受理，并于近日获得国家药监局批准。 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 近日，浙江昂利康制药股份有限公司（以下简称"公司"）收到国家药品监 督管理局（以下简称"国家药监局"）签发的《化学原料药上市申请批准通知书》。 现就相关情况公告如下： 一、批件基本信息 化学原料药名称：布比卡因 登记号：Y20230001273 生产企业名称：浙江昂利康制药股份有限公司 生产企业地址：绍兴嵊州市嵊州大道北 1000 号 布比卡因制剂临床上主要用于局部麻醉和术后镇痛。 三、对公司的影响 公司本次获得化学原料药布比卡因上市申请批准通知书，将进一步丰富公司 产品线，提升公司核心竞 ...

昂利康晚间公告，近日，公司收到国家药品监督管理局签发的《化学原料药上市申请批准通知书》。化 学原料药名称为布比卡因，登记号为Y20230001273。公司于2023年12月递交了布比卡因原料药的药品 注册申请，于2024年1月获得受理，并于近日获得国家药监局批准。布比卡因制剂临床上主要用于局部 麻醉和术后镇痛。本次获得化学原料药布比卡因上市申请批准通知书，将进一步丰富公司产品线，提升 公司核心竞争力。 ...

人民财讯11月17日电，昂利康（002940）11月17日公告，公司收到国家药品监督管理局签发的布比卡因 《化学原料药上市申请批准通知书》。布比卡因制剂临床上主要用于局部麻醉和术后镇痛。 ...